Yoshimasu Takashi, Ohtani Toshio, Sakamoto Taiko, Oshima Akihiro, Furukawa Fukumi
Department of Dermatology, Wakayama Medical University, 811-1 Kimiidera, Wakayama 641-0012, Japan.
Eur J Dermatol. 2002 Jan-Feb;12(1):50-2.
Tacrolimus is a prototype of a class of topical immunosuppressive agents with great potential for the treatment of inflammatory skin diseases. Topical tacrolimus therapy was applied to facial skin lesions in 11 cases of cutaneous lupus erythematosus (LE) and dermatomyositis. Of the 11 patients, 6 (3 systemic LE, one discoid LE and 2 dermatomyositis) showed a marked regression of their skin lesions after tacrolimus therapy, but 4 patients (3 discoid LE and one dermatomyositis) were resistant to the therapy. A good response was observed for facial erythematous lesions with edematous or telangiectatic changes in systemic LE and dermatomyositis. In discoid LE with typical discoid lesions, tacrolimus brought no improvement. Topical tacrolimus will become a new tool for managing the skin lesions of collagen diseases.
他克莫司是一类具有治疗炎性皮肤病巨大潜力的局部免疫抑制剂的原型。他克莫司局部治疗应用于11例皮肤性红斑狼疮（LE）和皮肌炎患者的面部皮肤损害。11例患者中，6例（3例系统性LE、1例盘状LE和2例皮肌炎）在他克莫司治疗后皮肤损害显著消退，但4例患者（3例盘状LE和1例皮肌炎）对该治疗耐药。在系统性LE和皮肌炎中，对于伴有水肿或毛细血管扩张改变的面部红斑性损害观察到良好反应。在具有典型盘状损害的盘状LE中，他克莫司未带来改善。局部应用他克莫司将成为治疗胶原病皮肤损害的一种新工具。
